Financial Data and Key Metrics Changes - Consolidated revenue increased by 14.3% or $17.1 million to $136.8 million, driven by strong performance in Genie Retail Energy [10] - Consolidated gross profit rose by 10.6% to $37.4 million, while gross margin decreased by 90 basis points to 27.3% [11][12] - Consolidated net income attributable to stockholders increased by $10.6 million or $0.40 per share from $8.1 million or $0.30 per share a year earlier [13] Business Line Data and Key Metrics Changes - Genie Retail Energy (GRE) revenue jumped 17.8% to $132.5 million, primarily due to investments made to grow the customer base [10] - Electricity revenue climbed 16.4% to $104.1 million, contributing 78.6% of GRE's revenues, with kilowatt hours sold increasing by 23.5% [10] - Revenue from natural gas sales increased by 26.8% to $28.4 million, reflecting increases in both terms sold and revenues per term sold [11] Market Data and Key Metrics Changes - Customer churn in the first quarter was 5.5%, unchanged from the year-ago quarter, indicating effective customer retention efforts [5] - The company ended the quarter with approximately 413,000 meters served, comprising 402,000 Residential Customer Equivalents (RCEs) [4] Company Strategy and Development Direction - The company is expanding its customer base and has begun marketing in California, with plans to offer gas in Kentucky in the second quarter [5] - The community solar project in Lansing, New York, is on track for completion in the third quarter and is expected to be EBITDA accretive immediately upon going online [6] Management's Comments on Operating Environment and Future Outlook - Management highlighted strong operational and financial results, indicating a return to normalized results for the retail energy business [3] - The company confirmed its full-year adjusted EBITDA guidance of $40 million to $50 million, suggesting confidence in future performance [14] Other Important Information - The company returned $3.9 million to stockholders through dividends and share repurchases during the first quarter [7] - Cash, cash equivalents, and marketable securities totaled $210.2 million as of March 31, 2025, an increase of $9.2 million in the quarter [13] Q&A Session Summary - There were no questions during the Q&A session, leading to the conclusion of the conference call [16]

Financial Data and Key Metrics Changes - The company reported revenue of $872 million for Q3 FY2025, an increase of 19% year-over-year and 5% sequentially [11][12] - Non-GAAP earnings per share (EPS) was $2.52, exceeding guidance [11][12] - Gross margin was reported at 12%, impacted by contra revenue from a warrant agreement [15][26] Business Line Data and Key Metrics Changes - Optical communications revenue was $657 million, up 11% year-over-year and 2% sequentially [12][14] - Datacom revenue was $251 million, down 18% year-over-year and 16% sequentially, primarily due to product transitions [12][14] - Telecom revenue reached $406 million, up 42% year-over-year and 17% sequentially, driven by strong demand in data center interconnect applications [12][14] Market Data and Key Metrics Changes - Automotive revenue increased by 76% year-over-year and 24% sequentially, reaching $129 million [14] - Industrial laser revenue was $40 million, up 33% year-over-year and 8% sequentially [14] - Non-optical communications revenue totaled $215 million, a 53% increase year-over-year and 15% sequentially [14] Company Strategy and Development Direction - The company announced a new commercial relationship with Amazon Web Services, expected to boost revenue starting in FY2026 [9][10] - Expansion plans are on track with Building 10 construction underway to meet long-term capacity needs [9][80] - The company remains optimistic about future growth driven by telecom system wins and the ramp of 1.6T datacom products [19][60] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the ability to execute well and maintain a consistent track record of revenue growth [10][19] - The company anticipates continued year-over-year growth in the fourth quarter, with revenue guidance between $860 million and $900 million [19] - Management noted that while there may be short-term margin headwinds due to product ramps, long-term growth drivers remain intact [58][60] Other Important Information - The company repurchased over $100 million worth of shares this fiscal year, with approximately $197 million remaining under the current authorization [17][9] - Effective GAAP tax rate was reported at 5.8%, with expectations for mid-single digits for the fiscal year [17] Q&A Session Summary Question: Datacom revenue decline specifics - Management clarified that the decline in Datacom revenue was primarily due to strong growth in the DCI segment, offsetting some of the decline in 800G products [22][23] Question: Gross margin influences - Management indicated that the $4 million impact from the warrant affected gross margin by about 40 basis points, but this is not expected to recur [25][26] Question: Datacom revenue transition - Management noted that the decline in 800G is more likely due to share allocation rather than inventory issues, with a significant ramp for 1.6T products expected [34][36] Question: Amazon engagement and margin opportunities - Management expects the relationship with Amazon to expand over time, with revenue ramping in FY2026 [39][40] Question: Telecom growth sustainability - Management expressed optimism about the sustainability of telecom growth, citing several strong growth factors [44][46] Question: Tariff impacts - Management reported no material impacts from tariffs to date, as customers are responsible for tariffs under FOB shipping terms [18][76] Question: Building 10 progress - Management confirmed that construction of Building 10 is on track, with an 18-month timeline for completion [80][81] Question: Amazon revenue potential - Management indicated that Amazon could potentially become a significant customer, with revenue ramping in FY2026 [88][92]

Financial Data and Key Metrics Changes - Worldwide revenue for the quarter reached $47.3 million, representing approximately 25% growth compared to the prior year [6][27] - U.S. revenue was $44.8 million, reflecting approximately 27% growth, driven by a 27.3% increase in procedure volume [7][28] - Gross profit was $37.7 million, an increase of $7.8 million or 26.2%, with a gross margin rate of 79.7%, improving by nearly 80 basis points [28] - Net loss narrowed to $6.5 million or $0.15 per diluted share, compared to a net loss of $10.9 million or $0.27 per diluted share in the prior year [29] Business Line Data and Key Metrics Changes - The company experienced broad-based demand for existing technologies and rapid adoption of new solutions launched last year [7][9] - The number of four implant Granite cases grew approximately 69% compared to the prior year period [14] - The introduction of iFuse Torque and iFuse Intra has expanded the market and accelerated procedure volume growth [11][12] Market Data and Key Metrics Changes - The total addressable market has increased to over $3.5 billion, with 25% cumulative procedure volume growth over the last three years [10][11] - The company is targeting nearly 100,000 degenerative procedures annually with the Granite product, which became eligible for transitional pass-through payment starting January 1, 2025 [14] - The pelvic trauma market, with nearly 60,000 potential target procedures annually, represents a $300 million market opportunity [18] Company Strategy and Development Direction - The company focuses on innovation, engagement, commercial execution, and operational excellence as key priorities [10] - A hybrid commercial model combining territory managers and clinical specialists with third-party agents is being utilized to enhance market reach [25] - The company plans to launch new products over the next twelve to eighteen months, including a new SI joint fusion solution and a breakthrough device targeting spine surgery [19][87] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the demand for solutions and the ability to maintain strong revenue growth despite macroeconomic uncertainties [32][56] - The company updated its full-year revenue guidance to a range of $193.5 million to $197.5 million, implying year-over-year growth of approximately 16% to 18% [33][34] - Management highlighted the importance of favorable reimbursement trends and the potential for continued growth in procedure volumes [15][56] Other Important Information - The company exited the quarter with $144.4 million in cash and marketable securities, with a total cash usage of $5.6 million, a 31.7% improvement over the prior year [30] - The company does not anticipate any material impact on gross margins or supply chain from proposed tariffs, as most manufacturing is domestic [31] Q&A Session Summary Question: Contribution from new products and channels to growth - Management noted broad-based growth across all modalities, with strong demand for new products launched in 2024 contributing to accelerating growth [39] Question: Drivers of strong gross margin and future expectations - Management attributed gross margin improvement to better-than-expected average selling prices and supply chain efficiencies, while remaining cautious about potential pressures [42][46] Question: Long-term growth potential and guidance - Management expressed confidence in sustained growth potential beyond 2025, driven by technology leadership and expanding physician engagement [55] Question: Sequential growth expectations and guidance update - Management indicated that while they expect to maintain strong growth, they are being prudent in their guidance due to macroeconomic conditions [64] Question: Operating expenses and growth expectations - Management highlighted that increased operating expenses are linked to R&D investments and sales commissions, but they expect to maintain healthy operating leverage [70]

Financial Data and Key Metrics Changes - The company reported revenue of $872 million for Q3 2025, an increase of 19% year-over-year and 5% sequentially [11] - Non-GAAP earnings per share (EPS) was $2.52, exceeding guidance [11][16] - Gross margin was reported at 12%, impacted by contra revenue from a warrant agreement [15][24] Business Line Data and Key Metrics Changes - Optical communications revenue was $657 million, up 11% year-over-year and 2% sequentially [12] - Datacom revenue was $251 million, down 18% year-over-year and 16% sequentially, primarily due to product transitions at a large customer [12][16] - Telecom revenue reached $406 million, up 42% year-over-year and 17% sequentially, driven by strong demand in data center interconnect applications [12][16] - Non-optical communications revenue was $215 million, up 53% year-over-year and 15% sequentially, with automotive revenue increasing by 76% [14][15] Market Data and Key Metrics Changes - The telecom market showed strong growth trends, expected to continue into Q4 2025 [6][17] - The automotive segment experienced outsized growth but may moderate in the near term [7][18] Company Strategy and Development Direction - The company announced a new commercial relationship with Amazon Web Services, expected to boost revenue starting in FY 2026 [7][8] - Expansion plans are on track with Building 10 construction underway to meet long-term capacity needs [9][78] - The company remains optimistic about future growth driven by new product ramps and strong demand in telecom and non-optical communications [17][58] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the ability to execute well and maintain a consistent track record of revenue growth [10][17] - The company anticipates continued year-over-year growth in Q4 2025, with revenue guidance between $860 million and $900 million [18] - Management noted that while there may be short-term margin headwinds due to new product ramps, long-term growth drivers remain intact [56][58] Other Important Information - The company repurchased over $100 million worth of shares this fiscal year, reflecting confidence in its financial position [9][16] - Effective GAAP tax rate was reported at 5.8%, with expectations for a mid-single-digit rate for the fiscal year [16] Q&A Session Summary Question: Datacom revenue decline specifics - Management clarified that the decline in Datacom revenue was primarily due to strong growth in the DCI segment, which offset some of the expected decline in 800 gig products [21][22] Question: Gross margin concerns - Management indicated that the $4 million impact from the warrant agreement affected gross margin by about 40 basis points, but this is not expected to recur [23][24] Question: Datacom revenue transition - Management noted that the decline in 800 gig products is more likely due to share allocation rather than inventory issues, with a significant ramp for 1.6 terabit products expected in the second half of the year [30][36] Question: Amazon engagement and margin opportunities - Management expects the relationship with Amazon to expand over time, with multiple product types being ramped, although significant revenue is anticipated in FY 2026 [37][39] Question: Telecom growth sustainability - Management expressed confidence in the sustainability of telecom growth, citing several strong growth factors including new system wins and improving market dynamics [42][44] Question: Tariff impacts - Management reported no material impacts from global tariffs to date, as customers typically handle tariffs under FOB shipping terms [17][75] Question: Building 10 construction timeline - Management confirmed that Building 10 is on track for an 18-month completion timeline, with potential for early production [78][79] Question: Amazon revenue potential - Management indicated that while specific revenue details cannot be disclosed, they are optimistic about the potential for significant revenue growth from Amazon [86][90]

Financial Data and Key Metrics Changes - Vertex Pharmaceuticals reported total revenue of $2,770 million for Q1 2025, representing a 3% growth compared to Q1 2024 [7][41] - U.S. revenue grew by 9% year-over-year, driven by ongoing patient demand and the early launch of AlifTrex [41] - Ex-U.S. revenue declined by 5% year-over-year, impacted by illegal copy products in Russia [42][43] - Non-GAAP earnings per share were $4.06, down from $4.76 in Q1 2024, primarily due to increased operating expenses [45] Business Line Data and Key Metrics Changes - The launch of AlifTrex, Vertex's fifth CF medicine, is showing positive early dynamics and feedback from physicians and patients [7][8] - Gernavix, the first oral non-opioid for moderate to severe acute pain, has been launched and is seeing early uptake [33][34] - CASJEVI generated $14 million in revenue during Q1 2025, indicating initial traction in the market [43] Market Data and Key Metrics Changes - The company is expanding its reach with the global launch of Kashyvi, a gene-edited therapy for sickle cell disease and beta thalassemia, with over 65 authorized treatment centers activated [28][30] - In the U.S., formal commercial coverage for Kashyvi is either in place or provided through single case agreements, with significant progress in Medicaid coverage [29][30] Company Strategy and Development Direction - Vertex is focused on commercialization and expanding its product portfolio, with a strong emphasis on advancing its R&D pipeline [7][8] - The company aims to bring most CF patients to normal levels of CFTR function through its next-generation CFTR regimen [12] - Vertex is also advancing multiple pivotal development programs in diabetic peripheral neuropathy, type one diabetes, and kidney diseases [8][19] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's growth trajectory, raising the low end of 2025 total revenue guidance to a range of $11.85 billion to $12 billion [45][46] - The company anticipates continued growth from its CF medicines and expects to ramp up revenue from Gernavix in the second half of 2025 [46][47] Other Important Information - Vertex ended Q1 2025 with $11.4 billion in cash and investments, having repurchased approximately $425 million worth of shares [45] - The company is committed to investing in R&D, with a guidance range for combined non-GAAP R&D and SG&A expenses set at $4.9 billion to $5 billion for the full year 2025 [48] Q&A Session Summary Question: Feedback on Elephthrex launch and chronic pain indications for Gernavix - Management noted that sweat chloride is not routinely used in clinical practice, but the combination of Elephthrex's benefits, including non-inferiority to Trikafta and additional mutation coverage, is compelling [56][58] Question: Impact of tariffs and Russia issue on CF business - The impact from the Russia issue is estimated at $100 million for Q1 and $200 million for the full year, which is included in current guidance [61][62] - Tariffs currently have an immaterial impact due to a well-balanced global supply chain and minimal exposure to China [62][63] Question: Early adopters of Elephthrex and payer coverage for Gernavix - Uptake of Elephthrex is seen across all patient groups, with the fastest uptake among those newly eligible for CFTR modulators [68] - Gernavix is being used in various settings, including surgery and non-surgery, with broad uptake and positive feedback from physicians [75]

Financial Data and Key Metrics Changes - Vertex Pharmaceuticals reported Q1 2025 revenue of $2,770 million, representing a 3% growth compared to Q1 2024 [5][38] - U.S. revenue grew by 9% year-over-year, driven by patient demand and the early launch of AlifTrex [38] - Non-GAAP earnings per share for Q1 2025 were $4.06, down from $4.76 in Q1 2024, primarily due to increased operating expenses and lower interest income [43] Business Line Data and Key Metrics Changes - The CF franchise continues to grow, with the launch of AlifTrex and ongoing global launch of Kashyvi contributing to revenue [21][26] - AlifTrex has shown strong early uptake, particularly among patients who are naive to CFTR modulators and those switching from Trikafta [24][66] - Gernavix, a new non-opioid treatment for acute pain, has been launched with positive early feedback and broad retail pharmacy stocking [30][31] Market Data and Key Metrics Changes - The company is expanding its market presence with new product launches and regulatory approvals in various regions, including the U.S., UK, and Europe [9][28] - The illegal copy product issue in Russia negatively impacted revenue, with an estimated $100 million impact in Q1 2025 [60][61] - The company has secured reimbursement access for Kashyvi in several countries, enhancing its market potential [28][78] Company Strategy and Development Direction - Vertex is focused on commercialization and expanding its product portfolio, with multiple launches and advancements in its R&D pipeline [5][6] - The company aims to bring innovative therapies to market, including the next-generation CFTR regimen and various pain management solutions [10][12] - Vertex is committed to maintaining attractive profitability while investing in R&D and commercial capabilities [46] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's growth trajectory, raising the low end of 2025 total revenue guidance to $11.85 billion [43][44] - The company anticipates continued growth from its CF medicines and expects to ramp up revenue from Gernavix in the second half of 2025 [45] - Management highlighted the importance of securing payer coverage and expanding access to new therapies as key drivers for future success [35][68] Other Important Information - Vertex has five programs in pivotal development, with multiple additional programs in early and mid-stage clinical trials [48] - The company ended Q1 2025 with $11.4 billion in cash and investments, having repurchased approximately $425 million worth of shares [43] Q&A Session Summary Question: Feedback on Elephthrex launch and sweat chloride as a biomarker - Management noted that sweat chloride is not routinely used in clinical practice, but the combination of Elephthrex's benefits, including non-inferiority to Trikafta and additional mutation coverage, is compelling [55][56] Question: Impact of tariffs on Vertex - Management confirmed that current tariffs have an immaterial impact due to a well-balanced global supply chain and minimal exposure to China [61][62] Question: Early adopters of Elephthrex and payer coverage for Gernavix - Uptake of Elephthrex is seen across various patient groups, with the fastest growth among those naive to CFTR modulators [66] - Gernavix is making progress with payers, aiming for broad coverage with minimal restrictions [68]

Financial Data and Key Metrics Changes - Total revenues for Q1 2025 were $99 million, reflecting a 4% increase compared to Q1 2024 [20] - Adjusted EBITDA increased approximately 1% from $17.3 million to $17.5 million in Q1 2025 [20] - Adjusted EBITDA margin was 17.7%, relatively flat compared to the previous year [21] - Gross margins decreased to 64.2% from 64.6% year over year due to lower revenue from higher margin products [22] Business Line Data and Key Metrics Changes - Strength graft revenues grew 19% on a constant currency basis in Q1 2025 [8] - On X revenue increased by 11% year over year on a constant currency basis [11] - BioGlue revenues grew 9% on a constant currency basis [12] - Tissue processing revenues declined 23% year over year due to the backlog caused by a cybersecurity incident [12] Market Data and Key Metrics Changes - Latin America and Asia Pacific saw constant currency revenue growth of 268% and 14% respectively in Q1 2025 [13] - North America revenues declined by 6% compared to Q1 2024 [21] - EMEA revenues increased by 14% year over year [21] Company Strategy and Development Direction - The company is focused on ramping up On X supply and clearing the tissue processing backlog, with expectations to be fully caught up by the end of Q3 2025 [7][13] - The ongoing launch of AMDS in the U.S. is a key growth driver, with approximately 150 facilities actively seeking approvals [10][11] - The company aims to leverage positive clinical data to expand market share for On X valves, particularly among younger patients [12][15] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving double-digit revenue growth and twice that rate for EBITDA in the future [19][29] - The company raised its full-year 2025 revenue guidance to a constant currency growth range of 11% to 14% [24] - Management noted that the impact of the cybersecurity incident is being resolved, with expectations for a return to normalcy in operations [6][29] Other Important Information - The company incurred approximately $4.7 million in Q1 related to the cybersecurity incident, which is excluded from adjusted EBITDA [22] - The net leverage ratio improved to 4.0 from 4.5 year over year [24] - The company does not anticipate the need to raise additional capital to fund its operations in the foreseeable future [22] Q&A Session Summary Question: Contribution of AMDS to growth and onboarding of facilities - Management indicated that AMDS contributed to the strong growth but did not break out specific numbers. They are encouraged by the reception from the clinical community and the onboarding process is progressing well [36][38] Question: Expectations for tissue growth recovery - Management expects to return to mid-single-digit growth for tissue processing by the end of the year, with the backlog being cleared in Q2 and Q3 [40][42] Question: Cash flow expectations for the year - Management expects to be free cash flow positive for the year, despite Q1 being seasonally high in expenses [54][56] Question: Growth rates for On X and stent grafts - Management expects On X to continue double-digit growth and stent grafts to grow at a mid-teens rate, with AMDS expected to improve overall growth rates [64][66] Question: Timing for acquiring Endospan - The option to acquire Endospan will trigger upon FDA approval, expected in the second half of 2026, with a decision required within 90 days of approval [72][74] Question: Feedback on Nexus data and market opportunity - Management expressed optimism about the Nexus data and its potential market impact, noting that the mortality benefits could lead to increased adoption [80][82]

Teleflex Incorporated (TFX) posted first-quarter 2025 adjusted earnings per share (EPS) from continuing operations of $2.91, down 9.3% from the year-ago quarter's figure. The metric topped the Zacks Consensus Estimate by 1%. GAAP EPS was $2.07 compared with $0.33 in the prior-year period. Following the announcement, shares of the company rose 0.4% last Friday. TFX's Revenues Net revenues fell 5% year over year (down 3.8% at constant exchange rate or CER) to $700.7 million. However, the metric surpassed the ...

Financial Data and Key Metrics Changes - Total product revenues for Q1 2025 were $121.5 million, representing a year-over-year growth of 62% compared to $75 million in Q1 2024 [16][17] - Net loss for Q1 2025 was $59.4 million or $1.22 per share, an improvement from a net loss of $68.4 million or $1.44 per share in Q1 2024 [20] - Cash and cash equivalents at the end of Q1 2025 were $300.9 million, down from $315.4 million at year-end [20] Business Line Data and Key Metrics Changes - Avelity net product sales were $96.2 million for Q1 2025, representing 80% year-over-year growth from $53.4 million in Q1 2024 [17] - Sunosi net product revenues were $25.2 million for Q1 2025, a 17% year-over-year increase from $21.6 million in Q1 2024 [17][18] - Avelity led the market in TRx growth in Q1 with approximately 167,000 prescriptions, reflecting 76% year-over-year growth [21] Market Data and Key Metrics Changes - Avelity coverage remained stable in Q1 with 78% of all lives covered across channels and 63% in the commercial segment [22] - Sunosi total prescriptions were over 46,000, representing a 12% growth versus Q1 2024 [23] - Payer coverage for Sunosi was stable with 83% of lives covered across channels [25] Company Strategy and Development Direction - The company aims to advance three novel NDA stage product candidates: AXS-fourteen for fibromyalgia, AXS-five for Alzheimer's disease agitation, and AXS-twelve for narcolepsy [6][10] - The company is focused on executing multiple Phase III clinical programs to broaden the potential of current products and candidates [6] - The company anticipates a strong launch for Cymbravo, with positive feedback from healthcare providers regarding its clinical profile [25] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's ability to navigate trade policy developments, stating that any potential impact would be immaterial [13] - The company expects 2025 to be a catalyst-rich year with potentially five marketed products across six indications by 2026 [15] - Management remains optimistic about achieving cash flow positivity based on the current operating plan [20][96] Other Important Information - The company has submitted an NDA for AXS-fourteen and anticipates a decision in Q2 2025 [7] - AXS-five has been granted breakthrough therapy designation by the FDA, with an sNDA submission planned for Q3 2025 [9] - The company is closely monitoring the competitive landscape, particularly regarding new entrants in the narcolepsy treatment space [35] Q&A Session Summary Question: Recent interactions with the FDA regarding developmental agents - Management indicated that dialogue with the FDA remains status quo and no changes have been noted regarding review teams or agency responsiveness [30] Question: DTC advertising plans for Avelity - A national campaign is expected to launch later this year, with a focus on engaging patients [34] Question: Coverage expectations for Avelity - Management aims to increase the number of covered lives and reduce utilization management barriers [68] Question: Expected cadence of coverage for Cymbravo - Management is focused on securing access quickly, acknowledging the competitive market [48] Question: Sales potential for AXS-fourteen in fibromyalgia - Management is enthusiastic about the market opportunity, with approximately 17 million people diagnosed in the U.S. [63] Question: Profitability outlook for 2025 - Management remains confident in achieving cash flow positivity but has not provided specific guidance on timing for profitability [96]

Core Viewpoint - Viavi Solutions Inc. reported strong third-quarter fiscal 2025 results, with revenues and net income exceeding expectations, driven by growth in the Network Enablement and Service Enablement segments, although macroeconomic challenges pose concerns for future spending [1][2]. Financial Performance - Net income on a GAAP basis was $19.5 million or 9 cents per share, a significant improvement from a net loss of $24.6 million or 11 cents per share in the prior year [2]. - Non-GAAP net income rose to $33.9 million or 15 cents per share, up from $13.2 million or 6 cents per share year-over-year, surpassing the Zacks Consensus Estimate by 3 cents [2]. Revenue Breakdown - Quarterly revenues reached $284.8 million, reflecting a 15.8% year-over-year increase, exceeding the Zacks Consensus Estimate of $282 million [3]. - The Network Enablement segment generated $188 million in net sales, a 23.9% increase from $151.7 million in the previous year, driven by strong demand from service providers and network equipment manufacturers [3]. - Service Enablement segment revenues were $20.2 million, up 11.6% year-over-year, supported by healthy demand trends [4]. - Optical Security and Performance Products revenues slightly increased to $76.6 million from $76.2 million, primarily due to strength in anti-counterfeiting products [4]. - Revenue contributions from different regions included $108.1 million from America, $100.7 million from Asia-Pacific, and $76 million from EMEA, showing respective increases from the previous year [5]. Margins and Operating Performance - Non-GAAP gross margin improved to 60%, up 210 basis points year-over-year, with the NE segment's gross margin at 63.4%, an increase of 190 basis points [6]. - Total non-GAAP operating margin increased by 740 basis points year-over-year to 16.7%, with the NSE business operating margin rising to 10.4% [7]. Cash Flow and Liquidity - The company generated $7.8 million in cash from operating activities during the quarter, a decrease from $19.5 million in the prior year [8]. - As of March 29, 2025, Viavi had $374.2 million in cash and cash equivalents and $396.1 million in long-term debt [8]. Outlook - For the fourth quarter of fiscal 2025, management anticipates revenues between $278 million and $290 million, with non-GAAP earnings per share expected to be between 10 cents and 13 cents [10]. - Projected revenues for the NSE business are between $203 million and $213 million, while the OSP segment is expected to generate revenues between $75 million and $77 million [10].